
  
    
      
        Background_NNP
        Sedation_NNP in_IN the_DT final_JJ stage_NN of_IN life_NN is_VBZ a_DT controversial_JJ
        issue_NN in_IN palliative_JJ care_NN with_IN regard_NN to_TO medical_JJ and_CC
        non-medical_JJ indications_NNS ,_, decision-making_NN and_CC ethical_JJ
        implications_NNS ._. It_PRP is_VBZ widely_RB agreed_VBN ,_, even_RB though_IN this_DT is_VBZ
        controversial_JJ too_RB ,_, that_IN in_IN patients_NNS with_IN advanced_JJ cancer_NN
        and_CC other_JJ terminal_NN diseases_NNS the_DT provision_NN of_IN sedation_NN
        leading_VBG to_TO unconsciousness_NNS sometimes_RB can_MD be_VB a_DT necessary_JJ
        therapeutic_JJ procedure_NN of_IN last_JJ resort_NN for_IN symptom_NN relief_NN [_NN 1_CD
        ]_NN ._. In_IN the_DT final_JJ stages_NNS of_IN life_NN ,_, symptoms_NNS may_MD remain_VB
        refractory_JJ ._. However_RB ,_, there_EX is_VBZ much_JJ debate_NN about_IN where_WRB to_TO
        draw_VB the_DT borderline_NN between_IN sedation_NN for_IN refractory_JJ
        symptoms_NNS that_WDT are_VBP of_IN a_DT mainly_RB physical_JJ /_NN somatic_JJ nature_NN and_CC
        for_IN those_DT psychological_JJ symptoms_NNS that_WDT are_VBP mainly_RB due_JJ to_TO
        existential_NN suffering_NN ._. Also_RB ,_, some_DT think_VBP that_DT sedation_NN
        leading_VBG to_TO unconsciousness_NNS should_MD be_VB an_DT option_NN ,_, or_CC an_DT
        alternative_NN ,_, for_IN terminally_RB ill_JJ patients_NNS with_IN intolerable_JJ
        suffering_NN if_IN they_PRP request_VBP euthanasia_NN or_CC physician_NN assisted_VBN
        suicide_NN [_NN 2_CD 3_CD 4_CD ]_NN or_CC for_IN those_DT who_WP just_RB want_VBP "_'' to_TO die_VB in_IN
        sleep_NN "_'' ._.
        The_DT problems_NNS associated_VBN with_IN sedation_NN in_IN end-of-life_JJ
        care_NN and_CC the_DT different_JJ attitudes_NNS among_IN clinicians_NNS and_CC
        palliative_JJ care_NN experts_NNS are_VBP reflected_VBN in_IN inconsistent_JJ
        terminology_NN [_NN 5_CD ]_NN ,_, variation_NN in_IN techniques_NNS used_VBN to_TO induce_VB ,_,
        maintain_VB and_CC monitor_VB sedation_NN [_NN 6_CD ]_NN ,_, duration_NN of_IN and_CC
        frequency_NN of_IN application_NN ,_, different_JJ concepts_NNS on_IN the_DT time_NN of_IN
        administering_VBG sedation_NN and_CC on_IN intentions_NNS [_NN 7_CD ]_NN ._. While_IN the_DT
        ambiguous_JJ term_NN "_'' terminal_NN sedation_NN (_( TS_NNP )_) "_'' [_NN 8_CD 9_CD ]_NN is_VBZ used_VBN
        most_RBS often_RB ,_, other_JJ terms_NNS more_RBR clearly_RB reflect_VB the_DT different_JJ
        viewpoints_NNS :_: "_'' sedation_NN for_IN intractable_JJ distress_NN in_IN the_DT
        imminently_RB dying_VBG [_NN 10_CD 11_CD ]_NN ;_: "_'' ,_, end-of-life_JJ sedation_NN [_NN 12_CD ]_NN
        "_'' slow-euthanasia_JJ "_'' [_NN 13_CD ]_NN ,_, "_'' palliative_JJ sedation_NN "_'' [_NN 14_CD ]_NN ,_,
        "_'' total_JJ sedation_NN "_'' [_NN 15_CD ]_NN ,_, "_'' sedation_NN in_IN the_DT final_JJ phase_NN "_'' ,_,
        "_'' palliative_JJ sedation_NN therapy_NN "_'' [_NN 16_CD ]_NN ._.
        Sedation_NNP in_IN the_DT terminal_NN or_CC final_JJ stages_NNS of_IN life_NN can_MD be_VB
        defined_VBN as_IN the_DT use_NN of_IN sedative_NN drugs_NNS (_( usually_RB
        benzodiazepines_NNS with_IN or_CC without_IN complementary_JJ opioids_NNS given_VBN
        by_IN the_DT intravenous_JJ or_CC by_IN the_DT subcutaneous_JJ route_NN )_) to_TO reduce_VB
        the_DT level_NN of_IN consciousness_NN sufficiently_RB deep_JJ to_TO provide_VB
        comfort_NN for_IN the_DT patient_NN until_IN death_NN occurs_VBZ ._. According_VBG to_TO
        the_DT EAPC_NNP Ethics_NNP Task_NNP Force_NNP "_'' terminal_NN '_'' or_CC '_POS palliative_JJ '_POS
        sedation_NN in_IN those_DT imminently_RB dying_VBG must_MD be_VB distinguished_VBN
        from_IN euthanasia_NN ._. In_IN terminal_NN sedation_NN the_DT 
        intention_NN is_VBZ to_TO relieve_VB intolerable_JJ
        suffering_NN ,_, the_DT 
        procedure_NN is_VBZ to_TO use_VB a_DT sedating_VBG drug_NN
        for_IN symptom_NN control_NN ,_, and_CC the_DT successful_JJ 
        outcome_NN is_VBZ the_DT alleviation_NN of_IN
        distress_NN ._. In_IN euthanasia_NN the_DT 
        intention_NN is_VBZ to_TO kill_VB the_DT patient_NN ,_, the_DT
        
        procedure_NN is_VBZ to_TO administer_VB a_DT lethal_JJ
        drug_NN and_CC the_DT successful_JJ 
        outcome_NN is_VBZ immediate_JJ death_NN ._. In_IN
        palliative_JJ care_NN mild_JJ sedation_NN may_MD be_VB used_VBN therapeutically_RB
        but_CC in_IN this_DT situation_NN it_PRP does_VBZ not_RB adversely_RB affect_VB the_DT
        patient_NN 's_POS conscious_JJ level_NN or_CC ability_NN to_TO communicate_VB [_NN 17_CD ]_NN
        ._. The_DT use_NN of_IN heavy_JJ sedation_NN (_( which_WDT leads_VBZ to_TO
        unconsciousness_NNS )_) may_MD sometimes_RB be_VB necessary_JJ to_TO achieve_VB
        identified_VBN therapeutic_JJ goals_NNS ._. The_DT intention_NN is_VBZ the_DT relief_NN
        of_IN otherwise_RB intractable_JJ and_CC refractory_JJ distress_NN [_NN 18_CD ]_NN ._.
        Target_NNP symptoms_NNS include_VBP persisting_VBG pain_NN ,_, delirium_NN ,_,
        dyspnoea_NN ,_, nausea_NN and_CC vomiting_NN ,_, massive_JJ haemorrhage_NN ,_,
        agitated_VBN anxiety_NN and_CC other_JJ forms_NNS of_IN psychological_JJ distress_NN ._.
        Sedation_NNP can_MD be_VB classified_VBN into_IN mild_JJ to_TO deep_JJ ,_, intermittent_JJ
        to_TO continuous_JJ ,_, primary_JJ to_TO secondary_JJ ,_, sudden_JJ to_TO slow_VB [_NN 19_CD ]_NN
        ._. Controversies_NNP exist_VB about_IN the_DT time_NN limit_NN and_CC proximity_NN to_TO
        death_NN [_NN 20_CD ]_NN ,_, the_DT clinical_JJ implications_NNS (_( e_SYM ._. g_SYM ._. the_DT
        withdrawal_NN of_IN nutrition_NN and_CC hydration_NN [_NN 21_CD 22_CD ]_NN )_) ,_, patient_NN
        monitoring_NN ,_, the_DT stage_NN and_CC circumstances_NNS of_IN the_DT illness_NN in_IN
        which_WDT sedation_NN can_MD be_VB offered_VBN or_CC employed_VBN ,_, and_CC the_DT informed_VBN
        consent_NN process_NN with_IN patients_NNS and_CC surrogates_NNS [_NN 23_CD ]_NN ._.
        Requests_NNP for_IN sedation_NN seem_VBP to_TO become_VB of_IN increasing_VBG
        relevance_NN in_IN advance_NN directives_NNS ,_, but_CC the_DT ethical_JJ
        implications_NNS may_MD rise_VB to_TO conflicts_NNS between_IN patients_NNS '_POS wishes_VBZ
        to_TO hasten_VB death_NN and_CC physicians_NNS '_POS intentions_NNS to_TO provide_VB the_DT
        best_JJS care_NN and_CC not_RB to_TO shorten_VB life_NN ._.
        In_IN particular_JJ ,_, there_EX is_VBZ controversy_NN on_IN the_DT issues_NNS of_IN
        dehydration_NN in_IN sedation_NN for_IN existential_NN suffering_VBG [_NN 24_CD ]_NN ._.
        The_DT increasing_VBG acceptance_NN and_CC use_NN of_IN "_'' terminal_NN sedation_NN "_'' [_NN
        25_CD ]_NN in_IN end-of-life_JJ care_NN makes_VBZ it_PRP necessary_JJ to_TO scrutinize_VB
        guidelines_NNS ,_, which_WDT may_MD help_VB to_TO continuously_RB consider_VB and_CC
        reconsider_VB the_DT needs_NNS and_CC wishes_NNS of_IN patients_NNS and_CC surrogates_NNS ,_,
        as_RB well_RB as_IN intentions_NNS and_CC concerns_NNS of_IN caregivers_NNS ._.
        The_DT use_NN of_IN sedation_NN in_IN terminally_RB ill_JJ patients_NNS has_VBZ been_VBN
        investigated_VBN by_IN a_DT number_NN of_IN studies_NNS in_IN recent_JJ years_NNS ._. The_DT
        wide_JJ variations_NNS in_IN frequency_NN to_TO choose_VB sedation_NN as_IN an_DT
        procedure_NN in_IN end-of-life_JJ care_NN across_IN different_JJ centres_NNS
        suggest_VBP different_JJ attitudes_NNS of_IN doctors_NNS and_CC policies_NNS of_IN
        institutions_NNS rather_RB than_IN the_DT patients_NNS '_POS preferences_NNS or_CC needs_VBZ
        [_NN 26_CD ]_NN ._. The_DT purpose_NN of_IN this_DT retrospective_NN study_NN was_VBD to_TO
        investigate_VB reasons_NNS for_IN the_DT request_NN and_CC the_DT application_NN of_IN
        sedation_NN in_IN terminal_NN situations_NNS in_IN our_PRP$ palliative_JJ care_NN unit_NN
        in_IN the_DT years_NNS 1995_CD -_: 2002_CD ,_, and_CC the_DT relevance_NN of_IN
        guidelines_NNS ._.
      
      
        Methods_NNP
        We_PRP performed_VBD a_DT systematic_JJ retrospective_NN analysis_NN of_IN the_DT
        charts_NNS of_IN all_DT patients_NNS who_WP received_VBD continuous_JJ or_CC
        intermittent_JJ sedation_NN by_IN the_DT administration_NN of_IN
        benzodiazepines_NNS intravenously_RB within_IN the_DT last_JJ 48_CD hrs_NNS before_IN
        death_NN in_IN the_DT Palliative_NNP Care_NNP Unit_NNP (_( PCU_NNP )_) of_IN GK_NNP Havelh√∂he_NNP
        between_IN 1995_CD and_CC 2002_CD ._. During_IN this_DT period_NN there_EX was_VBD no_DT
        change_NN in_IN the_DT medical_JJ staff_NN of_IN the_DT unit_NN ._. Indications_NNP ,_,
        decision-making_NN and_CC techniques_NNS were_VBD regulated_VBN according_VBG to_TO
        internal_JJ guidelines_NNS ,_, which_WDT were_VBD introduced_VBN after_IN discussion_NN
        with_IN the_DT medical_JJ and_CC nursing_NN staff_NN at_IN the_DT beginning_NN of_IN the_DT
        observation_NN period_NN (_( Table_NNP 1_LS )_) ._. Indication_NNP and_CC beginning_NN of_IN
        sedation_NN was_VBD documented_VBN in_IN the_DT medical_JJ records_NNS ._.
        The_DT medical_JJ charts_NNS of_IN all_DT patients_NNS (_( n_NN =_SYM 548_CD )_) ,_, who_WP died_VBD
        during_IN the_DT observation_NN period_NN where_WRB investigated_VBN in_IN order_NN
        to_TO find_VB out_RP those_DT ,_, who_WP had_VBD sedation_NN in_IN the_DT final_JJ stage_NN of_IN
        their_PRP$ life_NN ._. A_DT ranking_NN of_IN symptoms_NNS on_IN admission_NN ,_, during_IN
        treatment_NN and_CC in_IN the_DT last_JJ 48_CD hrs_NNS was_VBD made_VBN according_VBG to_TO our_PRP$
        symptom_NN assessment_NN scale_NN with_IN the_DT items_NNS :_: pain_NN ,_,
        gastrointestinal_NN (_( nausea_NN /_NN emesis_NNS /_NN intestinal_NN obstruction_NN )_) ,_,
        dyspnoea_NN ,_, anxiety_NN /_NN depression_NN ,_, fatigue_NN /_NN cachexia_NN ,_, cognitive_JJ
        disorder_NN /_NN delirium_NN (_( drowsiness_NNS /_NN agitation_NN )_) ,_, bleeding_VBG ,_, skin_NN
        problems_NNS (_( ulcerations_NNS ,_, oedema_NN )_) ,_, neurological_JJ and_CC others_NNS ._.
        Data_NNP collection_NN ,_, rating_NN and_CC analysis_NN was_VBD made_VBN by_IN a_DT single_JJ
        member_NN of_IN the_DT medical_JJ staff_NN ._. Reduction_NNP of_IN rating_NN and_CC
        ranking_JJ errors_NNS in_IN doubtful_JJ cases_NNS was_VBD achieved_VBN by_IN
        complementary_JJ interviews_NNS with_IN those_DT involved_VBN more_RBR
        personally_RB in_IN the_DT medical_JJ care_NN of_IN the_DT patients_NNS ._. In_IN this_DT
        study_NN the_DT single_JJ rater_NN method_NN (_( by_IN the_DT clinically_RB most_RBS
        experienced_VBN physician_NN )_) was_VBD preferred_VBN to_TO reduce_VB disagreement_NN
        on_IN symptom_NN definitions_NNS in_IN trust_NN on_IN the_DT experience_NN and_CC
        accuracy_NN of_IN an_DT individual_JJ point_NN of_IN view_NN though_IN recollection_NN
        of_IN data_NNS sometimes_RB was_VBD difficult_JJ to_TO obtain_VB ._. Charts_NNP of_IN
        patients_NNS with_IN sedation_NN were_VBD reviewed_VBN and_CC evaluated_VBN
        systematically_RB and_CC discussed_VBN with_IN those_DT involved_VBN in_IN the_DT
        decision-making_NN on_IN sedation_NN in_IN the_DT terminal_NN or_CC final_JJ phase_NN ._.
        A_DT ranking_NN was_VBD made_VBN to_TO identify_VB a_DT single_JJ predominant_NN
        symptom_NN ,_, which_WDT mainly_RB lead_VB to_TO sedation_NN and_CC concomitant_NN
        others_NNS ._. 6_CD predominant_NN symptoms_NNS for_IN sedation_NN were_VBD
        differentiated_JJ :_: dyspnoea_NN ,_, pain_NN ,_, delirium_NN /_NN agitation_NN ,_,
        gastrointestinal_NN ,_, bleeding_VBG ,_, anxiety_NN /_NN psychological_JJ distress_NN ._.
        The_DT recorded_VBN indications_NNS for_IN sedation_NN were_VBD classified_VBN into_IN
        "_'' mainly_RB physical_JJ "_'' when_WRB refractory_JJ physical_JJ symptoms_NNS
        predominated_JJ and_CC "_'' mainly_RB psychological_JJ "_'' ,_, when_WRB intolerable_JJ
        suffering_NN by_IN panic_NN anxiety_NN ,_, refractory_JJ insomnia_NN or_CC
        affective_JJ decompensation_NN persisted_VBD ._. Agitated_NNP delirium_NN was_VBD
        separated_JJ due_NN to_TO the_DT diagnostic_JJ uncertainty_NN to_TO relate_VB this_DT
        symptom_NN to_TO a_DT more_RBR physical_JJ or_CC more_RBR psychological_JJ origin_NN
        retrospectively_RB ._. Attention_NN was_VBD given_VBN to_TO the_DT stage_NN of_IN
        disease_NN at_IN the_DT time_NN of_IN admission_NN ,_, prevalence_NN of_IN symptoms_NNS on_IN
        admission_NN and_CC in_IN the_DT final_JJ phase_NN ,_, changes_NNS of_IN symptoms_NNS
        during_IN treatment_NN ,_, type_NN and_CC duration_NN of_IN sedation_NN until_IN
        death_NN ,_, survival_NN time_NN after_IN administration_NN of_IN the_DT sedatives_NNS ,_,
        provision_NN of_IN concomitant_NN therapy_NN ,_, nutrition_NN supply_NN and_CC
        fluids_NNS ,_, state_NN of_IN consciousness_NN and_CC communication_NN skills_NNS ._.
        Special_JJ interest_NN was_VBD given_VBN to_TO patients_NNS '_POS attitudes_NNS and_CC
        frequency_NN of_IN request_NN for_IN sedation_NN in_IN the_DT final_JJ phase_NN as_IN
        documented_VBN in_IN the_DT medical_JJ records_NNS or_CC in_IN advance_NN directives_NNS ._.
        Patients_NNS '_POS characteristics_NNS were_VBD related_VBN to_TO all_DT patients_NNS
        admitted_VBN ._.
        The_DT data_NNS were_VBD analysed_JJ using_VBG SPSS_NNP Version_NNP 11_CD ._.
        Chi-squared_NNP tests_NNS were_VBD used_VBN to_TO examine_VB associations_NNS between_IN
        categorical_JJ data_NNS ._. Metric_NNP data_NNS (_( age_NN ,_, duration_NN of_IN stay_NN ,_,
        duration_NN of_IN sedation_NN )_) were_VBD compared_VBN using_VBG Student_NNP 's_POS t-test_JJ
        for_IN independent_JJ groups_NNS ._. Comparisons_NNP between_IN groups_NNS for_IN
        predominant_NN symptoms_NNS were_VBD made_VBN using_VBG the_DT Mann-_NNP Whitney_NNP
        U-_NNP test_NN and_CC Wilcoxon_NNP rank-sum_JJ test_NN for_IN paired_VBN comparison_NN
        within_IN patients_NNS '_POS groups_NNS ._. P_NN <_NN ._. 05_CD was_VBD considered_VBN
        statistically_RB significant_JJ ._. On_IN the_DT base_NN of_IN these_DT data_NNS a_DT
        critical_JJ evaluation_NN for_IN the_DT decisions_NNS on_IN sedation_NN was_VBD made_VBN
        comparing_VBG the_DT periods_NNS between_IN 1995_CD -_: 1999_CD and_CC 2000_CD -_: 2002_CD ._.
      
      
        Results_NNS
        -_: Patients_NNPS '_POS characteristics_NNS showed_VBD no_DT significant_JJ
        difference_NN in_IN the_DT stage_NN of_IN disease_NN on_IN admission_NN (_( Table_NNP 2_LS )_) ._.
        But_CC patients_NNS who_WP finally_RB received_VBD sedation_NN were_VBD more_RBR likely_JJ
        to_TO have_VB experienced_VBN pain_NN ,_, dyspnoea_NN and_CC anxiety_NN as_IN the_DT
        predominant_NN symptom_NN on_IN admission_NN than_IN those_DT who_WP did_VBD not_RB
        undergo_VB sedation_NN (_( Table_NNP 4_LS )_) ._.
        -_: Sedation_NNP in_IN the_DT last_JJ 48_CD hrs_NNS was_VBD performed_VBN in_IN 14_CD ,_, 6_CD %_NN (_( n_NN
        =_SYM 80_CD )_) of_IN all_DT patients_NNS who_WP died_VBD in_IN the_DT PCU_NNP of_IN GK_NNP Havelhoehe_NNP
        (_( n_NN =_SYM 548_CD )_) with_IN significantly_RB increasing_VBG frequency_NN in_IN the_DT
        years_NNS 2000_CD -_: 2002_CD (_( œá_NN 2_CD =_SYM 8_CD ._. 57_CD ;_: p_NN =_SYM 0_CD ._. 003_CD )_) (_( Figure_NN 1_LS )_) ._.
        -_: No_DT difference_NN was_VBD found_VBN in_IN the_DT duration_NN of_IN stay_NN in_IN our_PRP$
        unit_NN until_IN death_NN between_IN those_DT patients_NNS who_WP died_VBD with_IN ,_, and_CC
        those_DT who_WP died_VBD without_IN sedation_NN ._. Mean_VB age_NN of_IN patients_NNS ,_, who_WP
        finally_RB had_VBD sedation_NN was_VBD less_JJR with_IN 54_CD years_NNS vs_NNS ._. 64_CD years_NNS in_IN
        those_DT without_IN sedation_NN (_( p_NN =_SYM 0_CD ._. 001_CD ,_, Student_NNP 's_POS t-test_JJ )_) ._.
        -_: All_DT patients_NNS had_VBD effective_JJ and_CC sufficient_JJ pain_NN
        control_NN ,_, but_CC in_IN those_DT patients_NNS who_WP were_VBD sedated_JJ in_IN the_DT last_JJ
        48_CD hrs_NNS of_IN life_NN ,_, burdensome_JJ dyspnoea_NN ,_, panic-stricken_JJ anxiety_NN
        and_CC agitated_VBN delirium_NN had_VBD increased_VBN during_IN the_DT stay_NN (_( Figure_NN
        2_LS )_) ._.
        -_: The_DT indications_NNS for_IN performing_VBG sedation_NN due_JJ to_TO
        predominant_NN psychological_JJ distress_NN (_( anxiety_NN ,_, refractory_JJ
        insomnia_NN ,_, decompensation_NN )_) and_CC due_JJ to_TO refractory_JJ symptoms_NNS
        (_( dyspnoea_NN ,_, gastrointestinal_NN ,_, pain_NN )_) did_VBD not_RB differ_VB
        significantly_RB during_IN the_DT two_CD observational_NN periods_NNS ._.
        Interestingly_RB ,_, there_EX was_VBD a_DT tendency_NN that_IN the_DT main_JJ
        indications_NNS for_IN sedation_NN during_IN the_DT last_JJ three_CD years_NNS
        shifted_VBD more_JJR and_CC more_JJR to_TO psychological_JJ distress_NN ._.
        -_: Mean_VB survival_NN time_NN after_IN administration_NN of_IN sedation_NN
        was_VBD 63_CD ¬±_NN 58_CD hrs_NNS during_IN the_DT whole_JJ observation_NN period_NN ._. In_IN the_DT
        years_NNS 2000_CD -_: 2002_CD patients_NNS with_IN more_RBR psychological_JJ distress_NN
        had_VBD a_DT longer_JJR survival_NN time_NN than_IN those_DT with_IN otherwise_RB
        resistant_JJ control_NN of_IN more_JJR physical_JJ symptoms_NNS (_( Table_NNP 3_LS )_) ._.
        -_: In_IN the_DT years_NNS 2000_CD -_: 2002_CD we_PRP noticed_VBD an_DT increase_NN in_IN the_DT
        request_NN for_IN sedation_NN in_IN the_DT final_JJ days_NNS of_IN life_NN from_IN 19_CD %_NN to_TO
        34_CD %_NN by_IN the_DT patients_NNS themselves_PRP ,_, documented_VBN in_IN personal_JJ
        statements_NNS or_CC advance_NN directives_NNS ._. In_IN those_DT patients_NNS in_IN
        which_WDT sedation_NN was_VBD given_VBN also_RB "_'' on_IN request_NN "_'' ,_, the_DT mean_JJ
        survival_NN time_NN was_VBD found_VBN to_TO be_VB slightly_RB shorter_JJR (_( 52_CD ¬±_NN 42_CD
        hrs_NNS )_) in_IN the_DT years_NNS 2000_CD -_: 2002_CD ,_, but_CC not_RB in_IN the_DT years_NNS before_IN
        (_( Table_NNP 3_LS )_) ._.
        -_: In_IN most_JJS cases_NNS ,_, sedation_NN was_VBD performed_VBN with_IN slowly_RB
        increasing_VBG doses_NNS of_IN midazolam_NN 0_CD ,_, 5_CD mg_NN -_: 8_CD mg_NN /_NN h_NN iv_NN ,_, aimed_VBN at_IN
        achieving_VBG effective_JJ symptom_NN control_NN ._. When_WRB this_DT was_VBD
        obtained_VBN ,_, doses_NNS were_VBD reduced_VBN and_CC sedation_NN was_VBD continued_VBN
        intermittently_RB with_IN the_DT documentation_NN of_IN the_DT level_NN of_IN
        consciousness_NN ,_, comfort_NN ,_, eating_VBG ,_, drinking_NN and_CC communication_NN
        skills_NNS ._. 48_CD patients_NNS had_VBD continuous_JJ sedation_NN (_( mean_VB duration_NN
        53_CD hrs_NNS )_) ,_, 32_CD intermittent_JJ (_( mean_VB duration_NN 77_CD hrs_NNS )_) ._. In_IN 53_CD
        patients_NNS (_( 66_CD %_NN )_) oral_JJ supply_NN of_IN fluids_NNS and_CC in_IN 10_CD patients_NNS
        also_RB oral_JJ nutrition_NN intake_NN during_IN sedation_NN was_VBD reported_VBN in_IN
        the_DT records_NNS ._. 27_CD patients_NNS (_( 33_CD ._. 8_CD %_NN )_) ,_, had_VBD no_DT oral_JJ fluid_NN or_CC
        nutrition_NN supply_NN after_IN sedation_NN was_VBD introduced_VBN either_CC
        because_IN of_IN the_DT deepness_NNS of_IN the_DT sedation_NN or_CC because_IN of_IN
        refusal_NN of_IN oral_JJ fluid_NN and_CC nutrition_NN intake_NN ._. Infusion_NN of_IN
        fluids_NNS was_VBD continued_VBN in_IN all_DT patients_NNS with_IN regard_NN on_IN comfort_NN
        according_VBG to_TO clinical_JJ signs_NNS of_IN thirst_NN with_IN restriction_NN of_IN
        volumes_NNS in_IN cases_NNS of_IN oedema_NN ,_, ascites_NNS and_CC pulmonary_JJ
        congestion_NN ._. Special_JJ attention_NN was_VBD given_VBN to_TO establish_VB a_DT good_JJ
        sleeping_NN period_NN at_IN night_NN and_CC a_DT more_JJR patient_NN controlled_VBD
        sedative_NN state_NN with_IN communicative_JJ skills_NNS and_CC reports_NNS of_IN
        comfort_NN during_IN the_DT day_NN ._.
        -_: Abilities_NNP to_TO communicate_VB like_IN asking_VBG for_IN help_NN or_CC
        answering_VBG questions_NNS on_IN pain_NN ,_, comfort_NN ,_, thirst_NN etc_FW ._. and_CC
        preserved_VBN forms_NNS of_IN cooperation_NN under_IN sedation_NN were_VBD reported_VBN
        in_IN 40_CD cases_NNS (_( 50_CD %_NN )_) ._.
        -_: The_DT following_VBG case_NN of_IN a_DT 40_CD yrs_NNS old_JJ hospice_NN worker_NN ,_, in_IN
        whom_WP oropharyngeal_NN cancer_NN was_VBD diagnosed_VBN during_IN pregnancy_NN ,_,
        may_MD illustrate_VB the_DT procedure_NN of_IN sedation_NN in_IN our_PRP$ PCU_NNP but_CC
        also_RB the_DT difficulties_NNS associated_VBN with_IN drawing_VBG the_DT line_NN in_IN
        consideration_NN of_IN patients_NNS needs_VBZ ,_, personal_JJ intentions_NNS and_CC
        adequacy_NN of_IN sedative_NN procedures_NNS for_IN refractory_JJ symptom_NN
        control_NN :_:
        
          For_IN several_JJ weeks_NNS she_PRP was_VBD treated_VBN for_IN
          panic_NN attacks_NNS ,_, dyspnoea_NN and_CC dysphagia_NN but_CC relief_NN of_IN
          symptoms_NNS only_RB lasted_VBD a_DT few_JJ days_NNS ._. Her_PRP$ weakness_NN increased_VBD
          rapidly_RB ._. In_IN her_PRP$ advance_NN directives_NNS she_PRP had_VBD disclaimed_JJ
          tracheotomy_NN and_CC antibiotics_NNS but_CC pleaded_VBD for_IN good_JJ pain_NN
          therapy_NN and_CC sedation_NN "_'' to_TO die_VB in_IN sleep_NN "_'' ._. In_IN the_DT final_JJ
          phase_NN she_PRP suffered_VBD from_IN extensive_JJ mucositis_NNS ,_, exhausting_JJ
          breathlessness_NNS and_CC agitated_VBN anxiety_NN by_IN upper_JJ airway_NN
          obstruction_NN due_JJ to_TO local_JJ tumour_NN progression_NN ,_, pulmonary_JJ
          and_CC hepatic_JJ metastases_NNS and_CC acute_JJ pneumonia_NN ._. She_PRP said_VBD :_: "_'' I_PRP
          think_VBP -_: now_RB the_DT time_NN has_VBZ come_VBN "_'' and_CC requested_VBD for_IN sedation_NN
          during_IN the_DT last_JJ hours_NNS of_IN her_PRP$ life_NN ._. The_DT clinical_JJ situation_NN
          was_VBD discussed_VBN with_IN the_DT nursing_NN team_NN according_VBG to_TO our_PRP$
          internal_JJ guidelines_NNS ._. Informed_NNP consent_NN in_IN presence_NN of_IN her_PRP$
          husband_NN was_VBD obtained_VBN before_IN 5_CD mg_NN iv_NN midazolam_NN were_VBD
          administered_VBN with_IN good_JJ symptom_NN relief_NN ._. Sedation_NNP was_VBD
          continued_VBN with_IN a_DT dosage_NN of_IN 1_CD -_: 2_CD mg_NN /_NN h_NN on_IN which_WDT the_DT patient_NN
          insisted_VBD on_IN comfort_NN by_IN the_DT sedation_NN and_CC fear_NN of_IN recurring_VBG
          distress_NN ._. Survival_NNP time_NN was_VBD 16_CD hrs_NNS in_IN a_DT peaceful_JJ ,_, quiet_JJ
          atmosphere_NN without_IN distress_NN ,_, a_DT light_JJ sedative_NN state_NN with_IN
          diminished_VBN communication_NN skills_NNS ,_, oral_JJ fluid_JJ intake_NN and_CC
          support_NN by_IN the_DT presence_NN of_IN her_PRP$ husband_NN ._. 
        
      
      
        Discussion_NNP
        To_TO balance_VB between_IN therapeutic_JJ sedation_NN to_TO reduce_VB
        burdensome_JJ distress_NN in_IN the_DT terminal_NN and_CC dying_VBG phase_NN and_CC
        sedation_NN in_IN patients_NNS who_WP voluntary_JJ request_NN sedation_NN "_'' to_TO die_VB
        in_IN sleep_NN "_'' is_VBZ a_DT difficult_JJ challenge_NN ._. This_DT is_VBZ particularly_RB
        important_JJ when_WRB anxiety_NN ,_, physical_JJ distress_NN and_CC anxiety_NN with_IN
        existential_NN suffering_VBG appear_VB together_RB in_IN the_DT dying_VBG person_NN
        like_IN in_IN the_DT illustrated_VBN case_NN ._.
        The_DT intention_NN of_IN this_DT survey_NN is_VBZ to_TO contribute_VB to_TO the_DT
        international_JJ discussion_NN on_IN sedation_NN in_IN end-of-life_JJ
        situations_NNS ._. The_DT analysis_NN was_VBD primarily_RB done_VBN to_TO reconsider_VB
        our_PRP$ internal_JJ guidelines_NNS by_IN reflecting_VBG our_PRP$ clinical_JJ practice_NN
        Certainly_RB a_DT survey_NN like_IN this_DT suffers_VBZ from_IN the_DT drawbacks_NNS of_IN
        a_DT retrospective_NN study_NN ._. Nevertheless_RB our_PRP$ results_NNS can_MD be_VB
        understood_VBN as_IN a_DT contribution_NN to_TO more_JJR transparency_NN in_IN this_DT
        difficult_JJ issue_NN ._. The_DT increasing_VBG incidence_NN and_CC also_RB the_DT
        finding_VBG that_DT sedation_NN was_VBD more_RBR often_RB used_VBN in_IN situations_NNS
        with_IN psychological_JJ distress_NN and_CC also_RB requested_VBN by_IN the_DT
        patients_NNS '_POS themselves_PRP may_MD indicate_VB an_DT increasing_VBG awareness_NN
        and_CC respect_NN for_IN the_DT needs_NNS of_IN the_DT patients_NNS ._. It_PRP also_RB seems_VBZ to_TO
        signify_VB that_IN in_IN the_DT care_NN of_IN patients_NNS with_IN physical_JJ symptoms_NNS
        and_CC psychological_JJ distress_NN in_IN situations_NNS near_IN death_NN needs_VBZ
        and_CC deficits_NNS exist_VBP ,_, for_IN which_WDT sensitive_JJ medical_JJ strategies_NNS
        must_MD be_VB combined_VBN and_CC integrated_VBN with_IN personal_JJ support_NN ,_,
        commitment_NN and_CC understanding_NN ._. In_IN our_PRP$ guidelines_NNS we_PRP tried_VBD to_TO
        relate_VB the_DT possible_JJ benefits_NNS of_IN sedation_NN to_TO the_DT basic_JJ
        concerns_NNS of_IN palliative_JJ care_NN by_IN using_VBG it_PRP as_IN a_DT reversible_JJ
        therapeutic_JJ procedure_NN ._. Concentrating_NNP on_IN communicated_VBN
        comfort_NN as_IN the_DT main_JJ indicator_NN for_IN the_DT value_NN of_IN this_DT option_NN
        means_VBZ also_RB ,_, that_IN in_IN the_DT care_NN of_IN the_DT sedated_JJ patients_NNS
        personal_JJ support_NN played_VBD an_DT important_JJ role_NN ._.
        Our_PRP$ decisions_NNS for_IN the_DT administration_NN of_IN sedation_NN were_VBD
        restricted_VBN to_TO terminal_NN and_CC final_JJ situations_NNS when_WRB the_DT course_NN
        of_IN the_DT disease_NN had_VBD so_RB progressed_VBN that_DT death_NN due_JJ to_TO the_DT
        underlying_VBG disease_NN could_MD be_VB expected_VBN within_IN the_DT next_JJ 48_CD hrs_NNS
        with_IN or_CC without_IN this_DT procedure_NN ._. Nevertheless_RB mean_VB survival_NN
        time_NN after_IN administration_NN of_IN sedation_NN was_VBD 63_CD hrs_NNS ._. It_PRP is_VBZ ,_, in_IN
        general_JJ ,_, difficult_JJ to_TO predict_VB death_NN in_IN a_DT particular_JJ patient_NN
        because_IN of_IN individual_JJ variations_NNS and_CC since_IN "_'' we_PRP do_VBP not_RB know_VB
        the_DT exact_JJ borderline_NN between_IN life_NN and_CC death_NN "_'' [_NN 27_CD ]_NN ._. To_TO a_DT
        certain_JJ extent_NN the_DT point_NN in_IN time_NN to_TO accept_VB dying_VBG -_: at_IN least_JJS
        in_IN medical_JJ institutions_NNS -_: depends_VBZ on_IN empirically_RB based_VBN
        decisions_NNS to_TO abstain_NN from_IN potentially_RB life-sustaining_JJ
        interventions_NNS e_SYM ._. g_SYM ._. pharmacological_JJ ,_, technical_JJ or_CC other_JJ
        artificial_JJ support_NN of_IN organ_NN function_NN "_'' to_TO prevent_VB death_NN "_'' at_IN
        least_JJS for_IN limited_JJ moments_NNS of_IN time_NN [_NN 28_CD 29_CD ]_NN ._. In_IN our_PRP$
        internal_JJ guidelines_NNS we_PRP grouped_VBN patients_NNS according_VBG to_TO the_DT
        staging_NN system_NN of_IN Jonen-_NNP Thielemann_NNP into_IN rehabilitative_JJ ,_,
        preterminal_NN ,_, terminal_NN and_CC final_JJ phases_NNS [_NN 30_CD ]_NN ._. With_IN
        relation_NN to_TO intentions_NNS of_IN care_NN ,_, life_NN expectancy_NN according_VBG
        to_TO the_DT progress_NN of_IN disease_NN and_CC empirical_JJ statistics_NNS ,_,
        consideration_NN on_IN perhaps_RB burdensome_JJ diagnostic_JJ and_CC
        therapeutic_JJ procedures_NNS and_CC communication_NN strategies_NNS with_IN
        patients_NNS and_CC proxies_NNS a_DT systematic_JJ staging_NN of_IN patients_NNS in_IN
        palliative_JJ care_NN on_IN expected_VBN outcome_NN seems_VBZ to_TO be_VB useful_JJ ._. The_DT
        predominant_NN classification_NN into_IN the_DT preterminal_NN stage_NN of_IN
        most_JJS of_IN our_PRP$ patients_NNS on_IN admission_NN signifies_NNS also_RB the_DT
        diagnostic_JJ uncertainty_NN and_CC difficulty_NN with_IN such_JJ a_DT staging_NN
        system_NN with_IN relationship_NN to_TO responsible_JJ decision-making_NN and_CC
        consequences_NNS of_IN care_NN ._.
        We_PRP considered_VBD sedation_NN as_IN a_DT an_DT palliative_JJ therapeutic_JJ
        option_NN of_IN last_JJ resort_NN in_IN the_DT last_JJ stages_NNS of_IN life_NN ._. Many_JJ
        experts_NNS prefer_VBP the_DT term_NN "_'' palliative_JJ sedation_NN "_'' instead_RB of_IN
        "_'' terminal_NN sedation_NN "_'' ._. Though_IN the_DT term_NN "_'' palliative_JJ sedation_NN "_''
        seems_VBZ to_TO be_VB more_RBR appropriate_JJ ,_, it_PRP must_MD be_VB distinguished_VBN from_IN
        those_DT situations_NNS in_IN other_JJ phases_NNS of_IN palliative_JJ care_NN ,_, when_WRB
        palliative_JJ sedation_NN is_VBZ used_VBN for_IN burdensome_JJ diagnostic_JJ or_CC
        painful_JJ therapeutic_JJ procedures_NNS (_( e_SYM ._. g_SYM ._. wound_VBD debridement_NN and_CC
        dressing_VBG of_IN exulcerating_VBG tumours_NNS ,_, insertion_NN of_IN catheters_NNS )_)
        and_CC usually_RB does_VBZ not_RB exceed_VB the_DT time_NN in_IN which_WDT the_DT procedure_NN
        is_VBZ undertaken_VBN ._. Among_IN the_DT most_RBS controversial_JJ discussed_VBN
        issues_NNS of_IN "_'' terminal_NN sedation_NN "_'' are_VBP the_DT questions_NNS of_IN when_WRB and_CC
        for_IN which_WDT forms_NNS of_IN intractable_JJ suffering_NN sedation_NN may_MD be_VB
        indicated_VBN ._. Another_DT central_JJ point_NN refers_VBZ to_TO the_DT question_NN of_IN
        how_WRB to_TO distinguish_VB clearly_RB the_DT crucial_JJ intention_NN of_IN relief_NN
        providing_VBG sedation_NN from_IN (_( slow_JJ )_) euthanasia_NN by_IN the_DT
        application_NN of_IN lethal_JJ doses_NNS of_IN sedatives_NNS [_NN 31_CD ]_NN ._.
        In_IN our_PRP$ study_NN we_PRP found_VBD that_DT dyspnoea_NN ,_, delirium_NN and_CC
        anxiety_NN increased_VBD during_IN the_DT treatment_NN period_NN in_IN those_DT
        patients_NNS who_WP finally_RB had_VBD sedation_NN while_IN pain_NN was_VBD
        significantly_RB reduced_VBN by_IN adequate_JJ treatment_NN during_IN the_DT
        progressing_VBG course_NN of_IN the_DT disease_NN (_( Figure_NN 2_LS )_) ._. This_DT finding_VBG
        is_VBZ in_IN confirmation_NN with_IN other_JJ studies_NNS ,_, in_IN which_WDT besides_IN
        acute_JJ bleeding_NN and_CC gastrointestinal_NN symptoms_NNS ,_, distressing_JJ
        dyspnoea_NN ,_, delirium_NN and_CC agitated_VBN anxiety_NN also_RB where_WRB found_VBD to_TO
        be_VB the_DT main_JJ reasons_NNS for_IN sedation_NN in_IN end-of-life_JJ care_NN [_NN 32_CD ]_NN
        ._. The_DT adequate_JJ treatment_NN and_CC care_NN of_IN patients_NNS of_IN patients_NNS
        with_IN otherwise_RB refractory_JJ symptoms_NNS certainly_RB is_VBZ a_DT great_JJ
        challenge_NN in_IN palliative_JJ care_NN and_CC improvement_NN in_IN this_DT field_NN
        is_VBZ needed_VBN urgently_RB ._. Our_PRP$ target_NN in_IN sedation_NN is_VBZ calming_JJ and_CC
        comfort_NN without_IN lowering_VBG the_DT level_NN of_IN consciousness_NN deep_JJ
        enough_RB to_TO loose_VB communication_NN ._. This_DT also_RB means_VBZ ,_, that_DT
        sedation_NN cannot_NN compensate_VB personal_JJ palliative_JJ support_NN and_CC
        care_NN -_: it_PRP must_MD be_VB combined_VBN ._. Our_PRP$ study_NN indicates_VBZ also_RB ,_, that_DT
        psychosocial_NN distress_NN contributed_VBD to_TO the_DT decision_NN making_VBG ,_,
        especially_RB when_WRB patients_NNS had_VBD made_VBN an_DT advance_NN directive_NN with_IN
        requests_NNS for_IN sedation_NN in_IN the_DT last_JJ phase_NN of_IN life_NN ._. In_IN our_PRP$
        study_NN the_DT shorter_JJR survival_NN time_NN after_IN administration_NN of_IN
        sedation_NN in_IN patients_NNS who_WP had_VBD made_VBN an_DT request_NN for_IN sedation_NN
        might_MD be_VB due_JJ to_TO the_DT fact_NN that_IN in_IN those_DT patients_NNS the_DT medical_JJ
        indications_NNS and_CC preconditions_NNS were_VBD considered_VBN more_RBR
        intensively_RB while_IN the_DT underlying_VBG disease_NN progressed_VBD ._.
        The_DT ethical_JJ dilemmas_NNS and_CC the_DT possibilities_NNS to_TO abuse_VB
        sedation_NN by_IN turning_VBG it_PRP in_IN a_DT form_NN of_IN medicalised_JJ killing_NN [_NN
        33_CD 34_CD ]_NN are_VBP important_JJ aspects_NNS that_WDT seem_VBP to_TO restrict_VB the_DT
        administration_NN of_IN sedatives_NNS in_IN terminally_RB ill_JJ patients_NNS ._. In_IN
        studies_NNS on_IN survival_NN time_NN of_IN patients_NNS with_IN and_CC without_IN
        sedation_NN no_DT significant_JJ differences_NNS were_VBD found_VBN ._. [_NN 35_CD 36_CD 37_CD
        ]_NN ._. Certainly_RB also_RB the_DT cultural_JJ background_NN determines_VBZ
        attitudes_NNS and_CC view_NN points_NNS to_TO the_DT goals_NNS of_IN care_NN and_CC in_IN which_WDT
        situations_NNS of_IN "_'' intolerable_JJ suffering_NN "_'' sedation_NN is_VBZ ethically_RB
        acceptable_JJ [_NN 38_CD ]_NN ._. In_IN several_JJ retrospective_NN and_CC
        prospective_JJ surveys_VBZ the_DT reported_VBN frequency_NN of_IN sedation_NN due_JJ
        to_TO intractable_JJ symptoms_NNS in_IN different_JJ palliative_JJ care_NN
        settings_NNS ranged_VBD from_IN 7_CD -_: 52_CD %_NN with_IN increasing_VBG incidence_NN
        especially_RB for_IN "_'' existential_NN suffering_VBG "_'' [_NN 39_CD 40_CD 41_CD ]_NN ._.
        Diagnostic_NNP criteria_NNS and_CC clinical_JJ preconditions_NNS for_IN the_DT
        consideration_NN of_IN sedation_NN in_IN patients_NNS with_IN far_RB advanced_VBD
        disease_NN have_VBP been_VBN described_VBN by_IN several_JJ authors_NNS [_NN 42_CD 43_CD 44_CD ]_NN
        ,_, but_CC aims_VBZ ,_, targets_NNS ,_, types_NNS of_IN sedation_NN and_CC decision_NN making_VBG
        remain_VB conflicting_JJ issues_NNS ._.
        In_IN modern_JJ Western_JJ culture_NN ,_, the_DT elements_NNS of_IN a_DT "_'' good_JJ
        death_NN "_'' include_VBP ,_, besides_IN freedom_NN of_IN pain_NN ,_, death_NN at_IN home_NN with_IN
        the_DT family_NN members_NNS being_VBG around_IN ,_, amongst_IN others_NNS also_RB the_DT
        element_NN of_IN "_'' awareness_NN "_'' ._. However_RB ,_, the_DT technical_JJ
        possibilities_NNS of_IN palliative_JJ care_NN with_IN concentration_NN on_IN
        quality_NN of_IN life_NN also_RB brought_VBD about_IN a_DT "_'' diminished_VBN emphasis_NN
        on_IN the_DT good_JJ death_NN "_'' [_NN 45_CD ]_NN ._. Consequently_RB ,_, the_DT increasing_VBG
        requests_NNS of_IN patients_NNS "_'' to_TO die_VB in_IN sleep_NN "_'' by_IN terminal_NN sedation_NN
        could_MD be_VB an_DT comprehensible_JJ alternative_NN to_TO euthanasia_NN or_CC
        physician-assisted_JJ suicide_NN and_CC must_MD be_VB reflected_VBN in_IN the_DT
        discussion_NN on_IN the_DT value_NN of_IN sedation_NN in_IN end-of-life_JJ care_NN ._.
        Though_IN we_PRP could_MD not_RB make_VB a_DT clear_JJ differentiation_NN between_IN
        primary_JJ (_( when_WRB patients_NNS want_VBP to_TO be_VB sedated_JJ approaching_VBG the_DT
        moment_NN of_IN death_NN )_) and_CC secondary_JJ sedation_NN (_( when_WRB sedation_NN
        results_NNS as_RB a_DT "_'' side-effect_JJ "_'' in_IN otherwise_RB refractory_JJ symptom_NN
        control_NN [_NN 46_CD ]_NN ,_, it_PRP must_MD be_VB clear_JJ to_TO all_DT ,_, that_IN the_DT
        intention_NN of_IN sedation_NN in_IN the_DT terminal_NN and_CC final_JJ phase_NN is_VBZ
        not_RB a_DT concealed_VBN form_NN of_IN euthanasia_NN [_NN 47_CD ]_NN ._. Under_IN ethical_JJ
        aspects_NNS the_DT requests_NNS for_IN sedation_NN to_TO reduce_VB consciousness_NN
        to_TO a_DT state_NN of_IN unawareness_NN need_VBP an_DT individual_JJ and_CC balanced_JJ
        approach_NN ,_, especially_RB when_WRB the_DT wish_NN for_IN sedation_NN is_VBZ not_RB
        connected_VBN with_IN the_DT intolerability_NN of_IN physical_JJ or_CC
        psychological_JJ distress_NN This_DT makes_VBZ it_PRP necessary_JJ to_TO discuss_VB
        the_DT problem_NN of_IN "_'' terminal_NN sedation_NN "_'' like_IN other_JJ forms_NNS of_IN
        therapeutic_JJ and_CC existential_NN support_NN with_IN patients_NNS and_CC
        family_NN members_NNS at_IN an_DT early_JJ stage_NN in_IN palliative_JJ care_NN ._.
        Sedation_NNP should_MD be_VB restricted_VBN as_IN a_DT reversible_JJ therapeutic_JJ
        option_NN to_TO otherwise_RB refractory_JJ suffering_NN by_IN burdensome_JJ
        symptoms_NNS in_IN the_DT terminal_NN and_CC final_JJ phase_NN ,_, which_WDT may_MD ,_, but_CC
        should_MD not_RB intentionally_RB ,_, hasten_VB death_NN ._. With_IN regard_NN to_TO
        symptom_NN relief_NN the_DT level_NN of_IN sedation_NN must_MD not_RB necessarily_RB
        need_VB "_'' deep_JJ sleep_NN "_'' or_CC bring_VB about_IN unconsciousness_NNS ._. The_DT
        recent_JJ consensus_NN guidelines_NNS for_IN dying_VBG intensive_JJ care_NN
        patients_NNS released_VBN in_IN Canada_NNP provide_VB a_DT clear_JJ ,_, but_CC certainly_RB
        also_RB problematic_JJ ,_, definition_NN of_IN terminal_NN sedation_NN which_WDT
        distinguishes_NNS between_IN "_'' real_JJ "_'' terminal_NN sedation_NN for_IN
        therapeutic_JJ intentions_NNS and_CC terminal_NN sedation_NN as_IN a_DT possible_JJ
        form_NN of_IN euthanasia_NN by_IN lethal_JJ doses_NNS of_IN sedatives_NNS ._. The_DT
        Canadian_JJ guidelines_NNS define_VB "_'' Terminal_NNP Sedation_NNP "_'' as_IN "_'' sedation_NN
        with_IN continuous_JJ IV_NNP narcotics_NNS and_CC /_NN or_CC sedatives_NNS until_IN the_DT
        patient_NN becomes_VBZ unconscious_JJ and_CC death_NN ensues_NNS from_IN the_DT
        underlying_VBG illness_NN "_'' ._. Emphasis_NNP is_VBZ added_VBN that_IN the_DT balance_NN
        between_IN possible_JJ euthanasia_NN and_CC inadequate_JJ palliative_JJ care_NN
        is_VBZ achieved_VBN by_IN titrating_VBG the_DT dosage_NN of_IN sedatives_NNS so_IN that_IN
        one_CD avoids_VBZ over-_NN or_CC under_IN medication_NN to_TO allow_VB death_NN to_TO
        result_VB from_IN the_DT underlying_VBG disease_NN in_IN a_DT state_NN of_IN continuing_VBG
        unconsciousness_NNS [_NN 48_CD ]_NN ._.
        According_VBG to_TO our_PRP$ guidelines_NNS after_IN the_DT intended_VBN provision_NN
        of_IN relief_NN and_CC symptom_NN alleviation_NN initially_RB our_PRP$ approach_NN in_IN
        most_JJS cases_NNS was_VBD to_TO reach_VB a_DT state_NN of_IN "_'' conscious_JJ sedation_NN "_'' by_IN
        reducing_VBG the_DT dosages_NNS of_IN sedatives_NNS to_TO a_DT level_NN of_IN
        communication_NN that_DT revalidation_NN of_IN the_DT clinical_JJ situation_NN
        could_MD be_VB achieved_VBN ._. This_DT form_NN of_IN a_DT patient_NN controlled_VBD
        sedative_NN state_NN was_VBD explained_VBN to_TO the_DT patients_NNS and_CC family_NN
        members_NNS before_IN induction_NN of_IN sedation_NN -_: especially_RB to_TO those_DT
        who_WP had_VBD a_DT request_NN for_IN sedation_NN in_IN their_PRP$ advance_NN directives_NNS ._.
        No_DT objection_NN to_TO this_DT procedure_NN was_VBD mentioned_VBN except_IN in_IN one_CD
        case_NN ,_, where_WRB a_DT female_JJ patient_NN requested_VBD for_IN sedation_NN after_IN
        an_DT emergency_NN operation_NN for_IN intestinal_NN obstruction_NN in_IN case_NN
        that_IN it_PRP would_MD not_RB bring_VB the_DT expected_VBN result_NN ._. The_DT intention_NN
        on_IN comfort_NN in_IN the_DT terminal_NN and_CC final_JJ phase_NN should_MD be_VB the_DT
        main_JJ concern_NN in_IN finding_VBG ethically_RB acceptable_JJ criteria_NNS for_IN
        the_DT use_NN of_IN sedation_NN in_IN end-of-life_JJ care_NN and_CC to_TO avoid_VB misuse_NN
        of_IN terminal_NN sedation_NN ._.
      
      
        Conclusions_NNP
        The_DT results_NNS of_IN our_PRP$ study_NN indicate_VBP that_DT sedation_NN in_IN
        end-of-life_JJ care_NN seems_VBZ to_TO become_VB an_DT increasing_VBG ethical_JJ
        problem_NN with_IN attention_NN to_TO patients_NNS '_POS wishes_VBZ and_CC needs_VBZ and_CC
        physicians_NNS '_POS integrity_NN ._. This_DT is_VBZ not_RB only_RB a_DT problem_NN for_IN those_DT
        involved_VBN in_IN palliative_JJ and_CC hospice_NN care_NN ._. "_'' Since_IN terminal_NN
        sedation_NN may_MD arguably_RB make_VB the_DT detection_NN of_IN
        euthanasia_NN /_NN assisted_VBN suicide_NN more_RBR difficult_JJ ._. ._. ._. the_DT intent_NN of_IN
        the_DT physician_NN is_VBZ the_DT most_RBS crucial_JJ distinction_NN "_'' [_NN 45_CD ]_NN ._. But_CC
        beside_IN intention_NN ,_, the_DT adequacy_NN of_IN what_WP is_VBZ done_VBN must_MD also_RB be_VB
        taken_VBN into_IN account_NN ._. The_DT concentration_NN on_IN comfort_NN and_CC
        symptom_NN alleviation_NN by_IN titrating_VBG the_DT sedative_NN medication_NN to_TO
        a_DT level_NN that_WDT allows_VBZ assessment_NN and_CC communication_NN are_VBP
        important_JJ aspects_NNS which_WDT should_MD be_VB considered_VBN in_IN the_DT ongoing_JJ
        discussion_NN on_IN sedation_NN in_IN the_DT last_JJ stages_NNS of_IN life_NN ._.
        Ethically_NNP acceptable_JJ criteria_NNS and_CC guidelines_NNS for_IN decision_NN
        making_VBG with_IN regard_NN to_TO the_DT nature_NN of_IN refractory_JJ and_CC
        intolerable_JJ symptoms_NNS ,_, patients_NNS '_POS needs_VBZ ,_, aims_NNS of_IN sedation_NN and_CC
        informed_VBN consent_NN are_VBP needed_VBN [_NN 49_CD ]_NN ._. Based_VBN on_IN these_DT ,_,
        prospective_JJ clinical_JJ studies_NNS with_IN systematic_JJ documentation_NN
        of_IN cases_NNS ,_, transparency_NN and_CC critical_JJ communication_NN with_IN
        regard_NN to_TO indications_NNS ,_, intentions_NNS ,_, procedures_NNS ,_,
        alternatives_NNS ,_, results_NNS and_CC adverse_JJ effects_NNS would_MD help_VB to_TO
        locate_VB the_DT appropriate_JJ place_NN of_IN sedation_NN in_IN end-of-life_JJ
        care_NN and_CC diminish_VB misuse_NN or_CC moral_JJ prejudices_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        HCMB_NNP participated_VBD in_IN the_DT design_NN ,_, data_NNS collection_NN ,_,
        analysis_NN ,_, and_CC drafting_VBG of_IN the_DT manuscript_NN ._.
        IA_NNP participated_VBD in_IN the_DT design_NN and_CC manuscript_NN editing_NN
        TJ_NNP participated_VBD in_IN the_DT design_NN and_CC manuscript_NN
        editing_NN ._.
      
    
  
